Immunosignaturing can detect products from molecular markers in brain cancer

Alexa K. Hughes, Zbigniew Cichacz, Adrienne Scheck, Stephen W. Coons, Stephen Johnston, Phillip Stafford

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer's disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifications of disease using samples from people with brain tumors. Blood samples from patients undergoing craniotomies for therapeutically naïve brain tumors with diagnoses of astrocytoma (23 samples), Glioblastoma multiforme (22 samples), mixed oligodendroglioma/astrocytoma (16 samples), oligodendroglioma (18 samples), and 34 otherwise healthy controls were tested by immunosignature. Because samples were taken prior to adjuvant therapy, they are unlikely to be perturbed by non-cancer related affects. The immunosignaturing platform distinguished not only brain cancer from controls, but also pathologically important features about the tumor including type, grade, and the presence or absence of O6-methyl-guanine-DNA methyltransferase methylation promoter (MGMT), an important biomarker that predicts response to temozolomide in Glioblastoma multiformae patients.

Original languageEnglish (US)
Article numbere40201
JournalPLoS One
Volume7
Issue number7
DOIs
StatePublished - Jul 16 2012

Fingerprint

Brain Neoplasms
Oligodendroglioma
Tumors
Brain
temozolomide
Glioblastoma
brain
neoplasms
genetic markers
Craniotomy
Astrocytoma
Guanine
Methyltransferases
Biomarkers
DNA Methylation
sampling
Alzheimer Disease
Blood
Infection
guanine

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Hughes, A. K., Cichacz, Z., Scheck, A., Coons, S. W., Johnston, S., & Stafford, P. (2012). Immunosignaturing can detect products from molecular markers in brain cancer. PLoS One, 7(7), [e40201]. https://doi.org/10.1371/journal.pone.0040201

Immunosignaturing can detect products from molecular markers in brain cancer. / Hughes, Alexa K.; Cichacz, Zbigniew; Scheck, Adrienne; Coons, Stephen W.; Johnston, Stephen; Stafford, Phillip.

In: PLoS One, Vol. 7, No. 7, e40201, 16.07.2012.

Research output: Contribution to journalArticle

Hughes, AK, Cichacz, Z, Scheck, A, Coons, SW, Johnston, S & Stafford, P 2012, 'Immunosignaturing can detect products from molecular markers in brain cancer', PLoS One, vol. 7, no. 7, e40201. https://doi.org/10.1371/journal.pone.0040201
Hughes, Alexa K. ; Cichacz, Zbigniew ; Scheck, Adrienne ; Coons, Stephen W. ; Johnston, Stephen ; Stafford, Phillip. / Immunosignaturing can detect products from molecular markers in brain cancer. In: PLoS One. 2012 ; Vol. 7, No. 7.
@article{82b41fa971f24a6894e7e41a7dc6026c,
title = "Immunosignaturing can detect products from molecular markers in brain cancer",
abstract = "Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer's disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifications of disease using samples from people with brain tumors. Blood samples from patients undergoing craniotomies for therapeutically na{\"i}ve brain tumors with diagnoses of astrocytoma (23 samples), Glioblastoma multiforme (22 samples), mixed oligodendroglioma/astrocytoma (16 samples), oligodendroglioma (18 samples), and 34 otherwise healthy controls were tested by immunosignature. Because samples were taken prior to adjuvant therapy, they are unlikely to be perturbed by non-cancer related affects. The immunosignaturing platform distinguished not only brain cancer from controls, but also pathologically important features about the tumor including type, grade, and the presence or absence of O6-methyl-guanine-DNA methyltransferase methylation promoter (MGMT), an important biomarker that predicts response to temozolomide in Glioblastoma multiformae patients.",
author = "Hughes, {Alexa K.} and Zbigniew Cichacz and Adrienne Scheck and Coons, {Stephen W.} and Stephen Johnston and Phillip Stafford",
year = "2012",
month = "7",
day = "16",
doi = "10.1371/journal.pone.0040201",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Immunosignaturing can detect products from molecular markers in brain cancer

AU - Hughes, Alexa K.

AU - Cichacz, Zbigniew

AU - Scheck, Adrienne

AU - Coons, Stephen W.

AU - Johnston, Stephen

AU - Stafford, Phillip

PY - 2012/7/16

Y1 - 2012/7/16

N2 - Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer's disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifications of disease using samples from people with brain tumors. Blood samples from patients undergoing craniotomies for therapeutically naïve brain tumors with diagnoses of astrocytoma (23 samples), Glioblastoma multiforme (22 samples), mixed oligodendroglioma/astrocytoma (16 samples), oligodendroglioma (18 samples), and 34 otherwise healthy controls were tested by immunosignature. Because samples were taken prior to adjuvant therapy, they are unlikely to be perturbed by non-cancer related affects. The immunosignaturing platform distinguished not only brain cancer from controls, but also pathologically important features about the tumor including type, grade, and the presence or absence of O6-methyl-guanine-DNA methyltransferase methylation promoter (MGMT), an important biomarker that predicts response to temozolomide in Glioblastoma multiformae patients.

AB - Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer's disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifications of disease using samples from people with brain tumors. Blood samples from patients undergoing craniotomies for therapeutically naïve brain tumors with diagnoses of astrocytoma (23 samples), Glioblastoma multiforme (22 samples), mixed oligodendroglioma/astrocytoma (16 samples), oligodendroglioma (18 samples), and 34 otherwise healthy controls were tested by immunosignature. Because samples were taken prior to adjuvant therapy, they are unlikely to be perturbed by non-cancer related affects. The immunosignaturing platform distinguished not only brain cancer from controls, but also pathologically important features about the tumor including type, grade, and the presence or absence of O6-methyl-guanine-DNA methyltransferase methylation promoter (MGMT), an important biomarker that predicts response to temozolomide in Glioblastoma multiformae patients.

UR - http://www.scopus.com/inward/record.url?scp=84862901532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862901532&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0040201

DO - 10.1371/journal.pone.0040201

M3 - Article

C2 - 22815729

AN - SCOPUS:84862901532

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e40201

ER -